These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32293433)

  • 1. A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency.
    Gandjour A
    BMC Health Serv Res; 2020 Mar; 20(1):240. PubMed ID: 32293433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule.
    Gandjour A
    Int J Health Plann Manage; 2015; 30(4):395-402. PubMed ID: 24789123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
    Persson U; Willis M; Odegaard K
    Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presenting Germany's drug pricing rule as a cost-per-QALY rule.
    Gandjour A
    Health Care Manag Sci; 2012 Jun; 15(2):103-7. PubMed ID: 22187356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
    Gandjour A
    Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs.
    Bach PB; Pearson SD
    JAMA; 2015 Dec; 314(23):2503-4. PubMed ID: 26619354
    [No Abstract]   [Full Text] [Related]  

  • 7. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does drug price-regulation affect healthcare expenditures?
    Ben-Aharon O; Shavit O; Magnezi R
    Eur J Health Econ; 2017 Sep; 18(7):859-867. PubMed ID: 27696009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
    Gress S; Niebuhr D; May U; Wasem J
    Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
    Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
    Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
    Mauskopf J; Chirila C; Birt J; Boye KS; Bowman L
    Health Policy; 2013 Apr; 110(1):49-59. PubMed ID: 23434292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Threshold value for reimbursement of costs of new drugs: cost-effectiveness research and modelling are essential links].
    Frederix GW; Hövels AM; Severens JL; Raaijmakers JA; Schellens JH
    Ned Tijdschr Geneeskd; 2015; 159():A7728. PubMed ID: 26083839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The German method for setting ceiling prices for drugs: in some cases less data are required.
    Gandjour A; Gafni A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):403-9. PubMed ID: 21831020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.
    Gandjour A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):65-71. PubMed ID: 21332250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of pharmaceutical rebates on patients' drug expenditures.
    Memedovich KA; Manns B; Beall R; Hollis A; Clement F
    CMAJ; 2019 Mar; 191(11):E308-E312. PubMed ID: 30885969
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead.
    Kaltenboeck A
    Value Health; 2020 Apr; 23(4):421-424. PubMed ID: 32327158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competition and price among brand-name drugs in the same class: A systematic review of the evidence.
    Sarpatwari A; DiBello J; Zakarian M; Najafzadeh M; Kesselheim AS
    PLoS Med; 2019 Jul; 16(7):e1002872. PubMed ID: 31361747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.